Objective:To investigate the risk factors and clinical features of Clostridium difficile infection (CDI) in ulcerative colitis (UC) patients. Methods:Clinical data of UC patients in hospital with complete CDI screening information at Department of Gastroenterology, The Second Hospital of Hebei Medical University from January 2015 to January 2018 were analyzed retrospectively. These patients were divided into two groups according to whether they were diagnosed with CDI. Demographic characteristics and clinical features of CDI in UC patients were analyzed. Univariate and multivariate analysis were used to reveal the risk factors of CDI.Result:A total of 162 UC patients were enrolled in this study, including 84 males and 78 females. Thirty-seven UC patients (22.8%) were diagnosed with CDI. Compared with the non-CDI group, the CDI group had a higher proportion of patients who used glucocorticoids (62.2% vs. 25.6%, P<0.05) and infliximab (13.5% vs. 1.6%, P<0.05) . The multivariate logistic regression analysis showed glucocorticoids treatment was the independent risk factor of CDI in UC patients ( OR = 4.111, 95% CI: 1.581-9.131, P = 0.001) . Conclusion:Systemic treatment with glucocorticoids increases the risk of CDI in UC patients.

Objective:To investigate the risk factors and clinical features of Clostridium difficile infection (CDI) in ulcerative colitis (UC) patients. Methods:Clinical data of UC patients in hospital with complete CDI screening information at Department of Gastroenterology, The Second Hospital of Hebei Medical University from January 2015 to January 2018 were analyzed retrospectively. These patients were divided into two groups according to whether they were diagnosed with CDI. Demographic characteristics and clinical features of CDI in UC patients were analyzed. Univariate and multivariate analysis were used to reveal the risk factors of CDI.Result:A total of 162 UC patients were enrolled in this study, including 84 males and 78 females. Thirty-seven UC patients (22.8%) were diagnosed with CDI. Compared with the non-CDI group, the CDI group had a higher proportion of patients who used glucocorticoids (62.2% vs. 25.6%, P<0.05) and infliximab (13.5% vs. 1.6%, P<0.05) . The multivariate logistic regression analysis showed glucocorticoids treatment was the independent risk factor of CDI in UC patients ( OR = 4.111, 95% CI: 1.581-9.131, P = 0.001) . Conclusion:Systemic treatment with glucocorticoids increases the risk of CDI in UC patients.

Objective:To study the clinical effect and safety of aerosol inhalation of recombinant human interferon α-2b( P. puti-da) in the children with viral upper respiratory tract infection ( VURI) . Methods: Totally 100 children diagnosed as viral upper re-spiratory tract infection were randomly divided into the observation group and the control group with 50 cases in each. The two groups of children were both given symptomatic and supportive treatment, and the observation group was given IFN-α2b (P. putida) 150 000 IU·kg-1 ·d-1 in 2-4 ml 0. 9% sodium chloride injection with aerosol inhalation, qd, 5-10 min each time, and the control group was given ribavirin 10-15 mg·kg-1 ·d-1 in 5% glucose injection 150 ml, ivd, and a course of treatment was continuous 5 d. The fever, cold symptoms ( catarrh, cough, malaise) and clinical efficiency of the two groups were compared. Results:The defervescence effect of the observation group was significantly higher than that of the control group after the treatment(P<0. 05). The effect in the children with mild and moderate cough in the observation group was better than that in the control group, and the changes were statistically sig-nificant difference(P<0. 01). The heat range, cough fading time, catarrh symptom and systemic symptom disappearance time in the observation group were significantly better than those in the control group(P<0. 05). The clinical efficient rate of the observation group was 96. 0%, which was significantly higher than that (84. 0%) in the control group(P<0. 05) . Conclusion: Combined with the conventional therapy, aerosol inhalation of IFN-α2b can be effectively and safely used for treating viral upper respiratory tract infec-tion in children, which is worthy of popularized use in clinics.

A simple and reliable high performance liquid chromatography (HPLC) method has been developed for the simultaneous quantification of five major bioactive components in ‘Shu-Jin-Zhi-Tong' capsules (SJZTC), for the purposes of quality control of this commonly prescribed traditional Chinese medicine. Under the optimum conditions, excellent separation was achieved, and the assay was fully validated in terms of linearity, precision, repeatability, stability and accuracy. The validated method was applied successfully to the determination of the five compounds in SJZTC samples from different production batches. The HPLC method can be used as a valid analytical method to evaluate the intrinsic quality of SJZTC.